Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 12, 983 (2006)
Published online: 30 August 2006 | doi:10.1038/nm0906-983a
Drug companies accused of stalling tailored therapies
Gunjan Sinha1
- Berlin
Abstract
Companies are reluctant to limit their market share, report says.
Therapies tailored for people's distinct genetic makeup have for years been touted as the next big thing in drug development. But if those drugs have yet to materialize, it may be because drug companies don't want them to.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Nanoelectronics The strain of it allNature Nanotechnology News and Views (01 Jul 2008)
